HLA-DQA1 and inflammatory bowel disease: This review aims to synthesize current knowledge on the molecular, immunogenetic, and clinical implications of HLA variants, particularly HLA-DQA1*05, in IBD patients receiving anti-TNF therapy, with a focus on refractoriness, immunogenicity, and prospects for precision medicine.